Role of PARP Inhibition in Recurrent Ovarian Cancer

Sofetabart mipitecan produced responses in heavily pretreated high-grade ovarian cancer regardless of folate receptor α expression or prior mirvetuximab soravtansine.

Indocyanine green may be highly sensitive in the identification of ovarian cancer metastases, though with low specificity.

Ursula A. Matulonis, MD, surveyed the exploitable genetic changes driving the next wave of ovarian cancer trials, from CDK2 and WEE1 inhibitors to PARG inhibitors.

Ursula A. Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a positive study.

Ursula A. Matulonis, MD, discussed how biomarkers, adverse effects, and patient preference guide choices among recent platinum-resistant ovarian cancer approvals.

In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus nivolumab caused no unexpected safety signals.